FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3176369543> ?p ?o ?g. }

• W3176369543 endingPage "74" @default.
• W3176369543 startingPage "74" @default.
• W3176369543 abstract "Abstract: Although some common therapies for cancers are available, many patients experience relapse during therapy. Therefore, an understanding of the pathogenesis of lung adenocarcinomas is needed in lung cancer therapies, especially targeted therapies. Immunotherapy has been shown to be effective in the therapy of various tumors, including non-small cell lung cancer (NSCLC). This study was aimed to review the morphology, pathogenesis, and immunotherapy of lung adenocarcinomas. This was a literature review study using databases of Clinical Key, Pubmed, and Google Scholar. The results showed that morphology of lung adenocarcinomas was characterized by the presence of lesions consisting of several morphological spectra, starting with pre-invasive lesions, then minimally invasive adenocarcinomas to invasive adenocarcinomas. Pathogenesis of lung adenocarcinomas was associated with genetic changes of several genes such as EGFR, KRAS, ALK, and ROS1; however, the most frequently involved were EGFR, KRAS, and ALK. The immunotherapies used for lung adeno-carcinomas were nivolumab, pembrolizumab, atezolizumab, tremelimumab, durvalumab, avelumab, cemiplimab, cetuximab, panitumumab, and matuzumab; however, the most commonly used were nivolumab, pembrolizumab, and atezolizumab. In conclusion, morphological spectra of lung adeno-carcinomas are pre-invasive lesions, minimally invasive adenocarcinomas, and invasive adeno-carcinomas. Pathogenesis of lung adenocarcinomas is associated with the presence of genetic changes, especially mutations of EGFR, KRAS and ALK. The most widely used immunotherapies for lung adenocarcinomas are nivolumab and pembrolizumab, which are included in the PD-1 antibody group and atezolizumab in the PD-L1 antibody group.Keywords: lung adenocarcinoma morphology; pathogenesis; immunotherapy Abstrak: Telah tersedia beberapa terapi umum kanker namun banyak pasien mengalami kekambuhan saat terapi. Oleh karena itu dibutuhkan pemahaman tentang patogenesis adenokarsinoma paru dalam terapi kanker paru khususnya terapi target. Imunoterapi dianggap sebagai teknologi yang memberikan harapan dan telah terbukti efektif dalam terapi berbagai tumor, termasuk non-small cell lung cancer (NSCLC). Penelitian ini bertujuan untuk menelaah morfologi, patogenesis, dan imunoterapi dari kanker paru tipe adenokarsinoma. Jenis penelitian ialah literature review menggunakan database Clinical Key, Pubmed, dan Google Scholar. Hasil penelitian mendapatkan morfologi adenokarsinoma paru ditandai adanya lesi yang terdiri dari beberapa spektrum morfologik, diawali dengan lesi preinvasif, selanjutnya lesi adenokarsinoma invasif minimal sampai adenokarsinoma invasif. Patogenesis adenokarsinoma paru berhubungan dengan perubahan genetik beberapa gen, yaitu EGFR, KRAS, ALK, dan ROS1; namun yang paling sering terlibat ialah EGFR, KRAS, dan ALK Imunoterapi yang digunakan untuk terapi adenokarsinoma paru ialah nivolumab, pembrolizumab, atezolizumab, tremelimumab, durvalumab, avelumab, cemiplimab, cetuximab, panitumumab, dan matuzumab; namun terbanyak digunakan ialah nivolumab, pembrolizumab, dan atezolizumab. Simpulan penelitian ini ialah spektrum morfologi dari adenokarsinoma paru berupa lesi preinvasif, adenokarsinoma invasif minimal, dan adenokarsinoma invasif. Patogenesis dari adenokarsinoma paru berhubungan dengan adanya perubahan genetik, terutama mutasi EGFR, KRAS, dan ALK. Imunoterapi yang paling banyak digunakan untuk terapi adenokarsinoma paru ialah nivolumab dan pembrolizumab yang termasuk dalam golongan antibodi PD-1 serta atezolizumab yang masuk dalam golongan antibodi PD-L1.Kata kunci: morfologi adenokarsinoma paru; patogenesis; imunoterapi" @default.
• W3176369543 created "2021-07-05" @default.
• W3176369543 creator A5000223381 @default.
• W3176369543 creator A5023084375 @default.
• W3176369543 creator A5042019677 @default.
• W3176369543 date "2021-05-05" @default.
• W3176369543 modified "2023-10-16" @default.
• W3176369543 title "Morfologi, Patogenesis, dan Imunoterapi Kanker Paru Tipe Adenokarsinoma" @default.
• W3176369543 doi "https://doi.org/10.35790/msj.3.1.2021.33544" @default.
• W3176369543 hasPublicationYear "2021" @default.
• W3176369543 type Work @default.
• W3176369543 sameAs 3176369543 @default.
• W3176369543 citedByCount "0" @default.
• W3176369543 crossrefType "journal-article" @default.
• W3176369543 hasAuthorship W3176369543A5000223381 @default.
• W3176369543 hasAuthorship W3176369543A5023084375 @default.
• W3176369543 hasAuthorship W3176369543A5042019677 @default.
• W3176369543 hasBestOaLocation W31763695431 @default.
• W3176369543 hasConcept C121608353 @default.
• W3176369543 hasConcept C126322002 @default.
• W3176369543 hasConcept C142724271 @default.
• W3176369543 hasConcept C143998085 @default.
• W3176369543 hasConcept C2775949291 @default.
• W3176369543 hasConcept C2776256026 @default.
• W3176369543 hasConcept C2777701055 @default.
• W3176369543 hasConcept C2777742743 @default.
• W3176369543 hasConcept C2780030458 @default.
• W3176369543 hasConcept C2780057760 @default.
• W3176369543 hasConcept C2780942790 @default.
• W3176369543 hasConcept C2781182431 @default.
• W3176369543 hasConcept C2781187634 @default.
• W3176369543 hasConcept C502942594 @default.
• W3176369543 hasConcept C526805850 @default.
• W3176369543 hasConcept C71924100 @default.
• W3176369543 hasConceptScore W3176369543C121608353 @default.
• W3176369543 hasConceptScore W3176369543C126322002 @default.
• W3176369543 hasConceptScore W3176369543C142724271 @default.
• W3176369543 hasConceptScore W3176369543C143998085 @default.
• W3176369543 hasConceptScore W3176369543C2775949291 @default.
• W3176369543 hasConceptScore W3176369543C2776256026 @default.
• W3176369543 hasConceptScore W3176369543C2777701055 @default.
• W3176369543 hasConceptScore W3176369543C2777742743 @default.
• W3176369543 hasConceptScore W3176369543C2780030458 @default.
• W3176369543 hasConceptScore W3176369543C2780057760 @default.
• W3176369543 hasConceptScore W3176369543C2780942790 @default.
• W3176369543 hasConceptScore W3176369543C2781182431 @default.
• W3176369543 hasConceptScore W3176369543C2781187634 @default.
• W3176369543 hasConceptScore W3176369543C502942594 @default.
• W3176369543 hasConceptScore W3176369543C526805850 @default.
• W3176369543 hasConceptScore W3176369543C71924100 @default.
• W3176369543 hasIssue "1" @default.
• W3176369543 hasLocation W31763695431 @default.
• W3176369543 hasOpenAccess W3176369543 @default.
• W3176369543 hasPrimaryLocation W31763695431 @default.
• W3176369543 hasRelatedWork W2745896026 @default.
• W3176369543 hasRelatedWork W2802256694 @default.
• W3176369543 hasRelatedWork W2923986778 @default.
• W3176369543 hasRelatedWork W2969038597 @default.
• W3176369543 hasRelatedWork W2981562389 @default.
• W3176369543 hasRelatedWork W3019495616 @default.
• W3176369543 hasRelatedWork W3118442307 @default.
• W3176369543 hasRelatedWork W3154458198 @default.
• W3176369543 hasRelatedWork W3215044659 @default.
• W3176369543 hasRelatedWork W4322754005 @default.
• W3176369543 hasVolume "3" @default.
• W3176369543 isParatext "false" @default.
• W3176369543 isRetracted "false" @default.
• W3176369543 magId "3176369543" @default.
• W3176369543 workType "article" @default.